We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Clovis' sNDA for Rubraca Gets Priority Review in the U.S.
Read MoreHide Full Article
Clovis Oncology announced the FDA has granted priority review to its supplemental new drug application (sNDA) looking for label expansion of its marketed drug, Rubraca (rucaparib).
The sNDA is looking to expand Rubraca’s label as a maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer regardless of a patient’s BRCA mutation status. With the FDA granting priority review, a response from the regulatory body is expected in Apr 6, 2018. Approval of the drug for this expanded indication will provide the company access to a wider population base of patients with ovarian cancer.
Notably, Rubraca is a PARP inhibitor, having received an accelerated approval in the United States in December 2016 for advanced ovarian cancer patients with deleterious BRCA mutation, previously treated with two or more chemotherapies.
Clovis’ shares are up almost 29.9% so far this year, significantly outperforming the industry’s 0.9% rally during the period.
The sNDA was submitted in October, based on promising data from the confirmatory phase III study, ARIEL 3, announced in June. Rubraca demonstrated a meaningful impact in delaying disease recurrence in advanced ovarian cancer patients, who are either BRCA mutant or HRD positive.
We remind investors that Rubraca as a monotherapy is also under review in the EU for treating advanced ovarian cancer. An opinion is expected later this month.
Clovis is also planning to file a marketing authorization application in early 2018 for maintenance treatment in the EU following the potential approval as monotherapy.
A potential approval in the EU and the label expansion in the United States are expected to boost the drug’s potential. It has generated sales of nearly $38.5 million in the first nine months of 2017 post its launch in December last year.
However, Clovis’ Rubraca is facing competition from other PARP inhibitors including Tesaro, Inc.'s Zejula and AstraZeneca's (AZN - Free Report) Lynparza as both these drugs are also approved to treat ovarian cancer irrespective of the BRCA-mutation.
Meanwhile, the second phase III confirmatory study, ARIEL4, is evaluating Rubraca compared with chemotherapy on patients, who have failed two prior lines of therapy. Clovis is also looking to expand Rubraca’s label into additional indications like prostrate, breast and pancreatic cancers among others either as monotherapy or in combination with other agents.
Other ongoing clinical analyses include phase II TRITON2 on prostate cancer and phase III TRITON3, a Tecentriq-Rubraca combination study on gynecologic cancers, sponsored by Roche (RHHBY - Free Report) .
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Clovis' sNDA for Rubraca Gets Priority Review in the U.S.
Clovis Oncology announced the FDA has granted priority review to its supplemental new drug application (sNDA) looking for label expansion of its marketed drug, Rubraca (rucaparib).
The sNDA is looking to expand Rubraca’s label as a maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer regardless of a patient’s BRCA mutation status. With the FDA granting priority review, a response from the regulatory body is expected in Apr 6, 2018. Approval of the drug for this expanded indication will provide the company access to a wider population base of patients with ovarian cancer.
Notably, Rubraca is a PARP inhibitor, having received an accelerated approval in the United States in December 2016 for advanced ovarian cancer patients with deleterious BRCA mutation, previously treated with two or more chemotherapies.
Clovis’ shares are up almost 29.9% so far this year, significantly outperforming the industry’s 0.9% rally during the period.
The sNDA was submitted in October, based on promising data from the confirmatory phase III study, ARIEL 3, announced in June. Rubraca demonstrated a meaningful impact in delaying disease recurrence in advanced ovarian cancer patients, who are either BRCA mutant or HRD positive.
We remind investors that Rubraca as a monotherapy is also under review in the EU for treating advanced ovarian cancer. An opinion is expected later this month.
Clovis is also planning to file a marketing authorization application in early 2018 for maintenance treatment in the EU following the potential approval as monotherapy.
A potential approval in the EU and the label expansion in the United States are expected to boost the drug’s potential. It has generated sales of nearly $38.5 million in the first nine months of 2017 post its launch in December last year.
However, Clovis’ Rubraca is facing competition from other PARP inhibitors including Tesaro, Inc.'s Zejula and AstraZeneca's (AZN - Free Report) Lynparza as both these drugs are also approved to treat ovarian cancer irrespective of the BRCA-mutation.
Meanwhile, the second phase III confirmatory study, ARIEL4, is evaluating Rubraca compared with chemotherapy on patients, who have failed two prior lines of therapy. Clovis is also looking to expand Rubraca’s label into additional indications like prostrate, breast and pancreatic cancers among others either as monotherapy or in combination with other agents.
Other ongoing clinical analyses include phase II TRITON2 on prostate cancer and phase III TRITON3, a Tecentriq-Rubraca combination study on gynecologic cancers, sponsored by Roche (RHHBY - Free Report) .
Clovis Oncology, Inc. Price
Clovis Oncology, Inc. Price | Clovis Oncology, Inc. Quote
Zacks Rank
Cloviscarries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>